WebFeb 23, 2024 · NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has commenced an underwritten … WebApr 10, 2024 · SELLAS Life Sciences Group - SLS News Today $1.41 -0.07 (-4.73%) (As of 03/9/2024 12:00 AM ET) Compare Today's Range $1.39 $1.54 50-Day Range $1.41 $3.86 52-Week Range $1.39 $7.40 Volume 670,667 shs Average Volume 818,164 shs Market Capitalization $29.03 million P/E Ratio N/A Dividend Yield N/A Price Target $7.00 Profile …
SLS (Sellas Life Sciences) Stock Technical Analysis 11/14/2024
WebFeb 23, 2024 · About SELLAS Life Sciences Group Inc SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the … WebSELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. toy story sids toys
Investors - Events & Presentations, Sellas Life Sciences
WebSELLAS Life Sciences Group Inc NASDAQ 2.72 0.02 (0.74%) Jan 9, 2024, 4:00:00 PM EST Overview Owners Insiders Short Interest Options Filings Financials Dividends Earnings Forecast Introduction This short interest tracker provides a variety of short interest related data, sourced from a variety of partners. WebApr 6, 2024 · Galinpepimut-S Update Call. SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with … WebApr 11, 2024 · Of the 19 institutional investors that purchased SELLAS Life Sciences Group stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Vanguard Group Inc. ($0.15M), Bank of Montreal Can ($0.11M), Geode Capital Management LLC ($82.24K), Marshall Wace LLP ($65.37K), Dimensional … toy story sid toys names